Barriers to Timely Lung Cancer Care in Early Stage Non-Small Cell Lung Cancer and Impact on Patient Outcomes

Overview

Journal Clin Lung Cancer

Publisher Elsevier

Specialties Oncology
Pulmonary Medicine

Date 2023 Nov 19

PMID 37981476

Authors

Mina Pirzadeh

Madeline Lagina

Cameron Wood

Thomas Valley

Nithya Ramnath

Douglas Arenberg

Jane C Deng

Affiliations

Soon will be listed here.

Abstract

Background: Optimal time to treatment for early-stage lung cancer is uncertain. We examined causes of delays in care for Veterans who presented with early-stage non-small cell lung cancer (NSCLC) and whether workup time was associated with increased upstaging or all-cause mortality.

Methods: We performed a retrospective analysis of Veterans referred to our facility with radiographic stage I or II NSCLC between January 2013 to December 2017, with follow-up through October 2021. Patient demographics, tumor characteristics, time intervals of care, and reasons for delays were collected. Guideline concordance (GC) was defined as treatment within 14 weeks of abnormal image. Multivariable analyses were performed to determine association between delays in care, survival, and upstaging.

Results: Data from 203 Veterans were analyzed. Median time between abnormal imaging to treatment was 17.7 weeks (IQR 12.7-26.6). Only 33% of Veterans received GC care. Most common patient-related delays were: intercurrent hospitalization/comorbidity (23%), no-shows (16%) and inability to reach Veteran (17%). Most common system-related delay: lack of scheduling availability (25%). Delays associated with upstaging: transportation issues, request for coordination of appointments, and unforeseen appointment changes. Rates of upstaging did not differ between GC and discordant groups (P = .6). GC care was not an independent predictor of mortality. Post-hoc, treatment within 8 weeks was associated with lower rates of upstaging (P = .05).

Conclusion: Although GC care did not impact survival or upstaging for early-stage NSCLC, shorter timeframes may be beneficial. Modifiable delays in care exist which may be addressed at an institutional level to improve timeliness of care.

References

Aberle D, Adams A, Berg C, Black W, Clapp J, Fagerstrom R . Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365(5):395-409. PMC: 4356534. DOI: 10.1056/NEJMoa1102873. View

Roberts T, Lennes I, Hawari S, Sequist L, Park E, Willers H . Integrated, Multidisciplinary Management of Pulmonary Nodules Can Streamline Care and Improve Adherence to Recommendations. Oncologist. 2019; 25(5):431-437. PMC: 7216451. DOI: 10.1634/theoncologist.2019-0519. View

Stokes S, Wakeam E, Swords D, Stringham J, Varghese Jr T . Impact of insurance status on receipt of definitive surgical therapy and posttreatment outcomes in early stage lung cancer. Surgery. 2018; 164(6):1287-1293. DOI: 10.1016/j.surg.2018.07.020. View

Raghavan D, Wheeler M, Doege D, Doty 2nd J, Levy H, Dungan K . Initial Results from Mobile Low-Dose Computerized Tomographic Lung Cancer Screening Unit: Improved Outcomes for Underserved Populations. Oncologist. 2019; 25(5):e777-e781. PMC: 7216453. DOI: 10.1634/theoncologist.2019-0802. View

de Koning H, van der Aalst C, de Jong P, Scholten E, Nackaerts K, Heuvelmans M . Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med. 2020; 382(6):503-513. DOI: 10.1056/NEJMoa1911793. View

Meza R, Jeon J, Toumazis I, Ten Haaf K, Cao P, Bastani M . Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography: Modeling Study for the US Preventive Services Task Force. JAMA. 2021; 325(10):988-997. PMC: 9208912. DOI: 10.1001/jama.2021.1077. View

Olsson J, SCHULTZ E, Gould M . Timeliness of care in patients with lung cancer: a systematic review. Thorax. 2009; 64(9):749-56. DOI: 10.1136/thx.2008.109330. View

Hanna T, King W, Thibodeau S, Jalink M, Paulin G, Harvey-Jones E . Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ. 2020; 371:m4087. PMC: 7610021. DOI: 10.1136/bmj.m4087. View

Zullig L, Sims K, McNeil R, Williams C, Jackson G, Provenzale D . Cancer Incidence Among Patients of the U.S. Veterans Affairs Health Care System: 2010 Update. Mil Med. 2017; 182(7):e1883-e1891. PMC: 5650119. DOI: 10.7205/MILMED-D-16-00371. View

10.

Mackintosh J, Marshall H, Yang I, Bowman R, Fong K . A retrospective study of volume doubling time in surgically resected non-small cell lung cancer. Respirology. 2014; 19(5):755-62. DOI: 10.1111/resp.12311. View

11.

Heiden B, Eaton Jr D, Engelhardt K, Chang S, Yan Y, Patel M . Analysis of Delayed Surgical Treatment and Oncologic Outcomes in Clinical Stage I Non-Small Cell Lung Cancer. JAMA Netw Open. 2021; 4(5):e2111613. PMC: 8160592. DOI: 10.1001/jamanetworkopen.2021.11613. View

12.

Gould M, Ghaus S, Olsson J, Schultz E . Timeliness of care in veterans with non-small cell lung cancer. Chest. 2008; 133(5):1167-73. DOI: 10.1378/chest.07-2654. View

13.

Sainz Zuniga P, Ost D . Impact of Delays in Lung Cancer Treatment on Survival. Chest. 2021; 160(5):1934-1958. DOI: 10.1016/j.chest.2021.08.051. View

14.

Howlader N, Forjaz G, Mooradian M, Meza R, Kong C, Cronin K . The Effect of Advances in Lung-Cancer Treatment on Population Mortality. N Engl J Med. 2020; 383(7):640-649. PMC: 8577315. DOI: 10.1056/NEJMoa1916623. View

15.

Berchuck J, Meyer C, Zhang N, Berchuck C, Trivedi N, Cohen B . Association of Mental Health Treatment With Outcomes for US Veterans Diagnosed With Non-Small Cell Lung Cancer. JAMA Oncol. 2020; 6(7):1055-1062. PMC: 7273310. DOI: 10.1001/jamaoncol.2020.1466. View

16.

Detterbeck F . The eighth edition TNM stage classification for lung cancer: What does it mean on main street?. J Thorac Cardiovasc Surg. 2017; 155(1):356-359. DOI: 10.1016/j.jtcvs.2017.08.138. View

17.

Becker N, Motsch E, Trotter A, Heussel C, Dienemann H, Schnabel P . Lung cancer mortality reduction by LDCT screening-Results from the randomized German LUSI trial. Int J Cancer. 2019; 146(6):1503-1513. DOI: 10.1002/ijc.32486. View

18.

Vidaver R, Shershneva M, Hetzel S, Holden T, Campbell T . Typical Time to Treatment of Patients With Lung Cancer in a Multisite, US-Based Study. J Oncol Pract. 2016; 12(6):e643-53. DOI: 10.1200/JOP.2015.009605. View

19.

Krist A, Davidson K, Mangione C, Barry M, Cabana M, Caughey A . Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021; 325(10):962-970. DOI: 10.1001/jama.2021.1117. View

20.

Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View